A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

Pertuzumab plus trastuzumab and chemotherapy for HER2- positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised,

Bevacizumab plus weekly paclitaxel improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC), but its use has been questioned due to the absence of

Triple-negative breast cancer (TNBC) is am immunohistochemically-defined breast cancer subtype negative for ER, PR and HER2 expression, with dismal prognosis that

The aim of this study was to examine the possible association between CNVs in five genes related to the PI3K/AKT pathway, HER2, FGFR1, PIK3CA, AKT3 and MDM2, and the efficacy

Abstract: The aim of this longitudinal study was to determine whether a rowing training program improved the quality of life and the physical activity levels in female breast

• Patients with advanced HER2-positive breast cancer, who have been treated with two or more lines of anti- HER2 therapy, may benefit from a third or further line of anti-HER2

The objective of the present work was to develop a soy protein-based edible coating with antioxidant activity and to evaluate the combined effect of selected edible

In the setting of HER2-positive breast cancer, four phase III neoadjuvant trials testing trastuzumab plus another anti-HER2 agent versus trastuzumab alone have shown